Drug intelligence / Profile preview

AT-104

Development stage: Discontinued
Lead developer: Applied Therapeutics
Modality: Small Molecules

Overview

AT-104 is a preclinical-stage PI3k inhibitor product that was being developed by Applied Therapeutics under a license agreement with Columbia University. It was intended for the treatment of lymphoid malignancies. The development program for AT-104 was terminated in July 2022 due to regulatory changes impacting PI3k inhibitors and Applied Therapeutics' decision to discontinue its early-stage preclinical PI3k program.

Targets

PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on AT-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-104.

Explore the full profile